Search by Drug Name or NDC
NDC 00338-9581-02 doxorubicin hydrochloride, Liposomal 2 mg/mL Details
doxorubicin hydrochloride, Liposomal 2 mg/mL
doxorubicin hydrochloride, Liposomal is a INTRAVENOUS INJECTION, SUSPENSION, LIPOSOMAL in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Baxter Healthcare Corporation. The primary component is DOXORUBICIN HYDROCHLORIDE.
Product Information
| NDC | 00338-9581 |
|---|---|
| Product ID | 0338-9581_f713b9ab-9d6e-4390-ae8e-f116cf7691f4 |
| Associated GPIs | |
| GCN Sequence Number | 024447 |
| GCN Sequence Number Description | doxorubicin HCl peg-liposomal VIAL 2 MG/ML INTRAVEN |
| HIC3 | V1D |
| HIC3 Description | ANTIBIOTIC ANTINEOPLASTICS |
| GCN | 47343 |
| HICL Sequence Number | 010222 |
| HICL Sequence Number Description | DOXORUBICIN HCL PEGYLATED LIPOSOMAL |
| Brand/Generic | Brand |
| Proprietary Name | doxorubicin hydrochloride, Liposomal |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | doxorubicin hydrochloride |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SUSPENSION, LIPOSOMAL |
| Route | INTRAVENOUS |
| Active Ingredient Strength | 2 |
| Active Ingredient Units | mg/mL |
| Substance Name | DOXORUBICIN HYDROCHLORIDE |
| Labeler Name | Baxter Healthcare Corporation |
| Pharmaceutical Class | Anthracycline Topoisomerase Inhibitor [EPC], Anthracyclines [CS], Topoisomerase Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE |
| Application Number | n/a |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00338-9581-02 (00338958102)
| NDC Package Code | 0338-9581-02 |
|---|---|
| Billing NDC | 00338958102 |
| Package | 1 VIAL, SINGLE-USE in 1 CARTON (0338-9581-02) / 10 mL in 1 VIAL, SINGLE-USE (0338-9581-01) |
| Marketing Start Date | 2023-12-19 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |